S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

$46.78
-0.94 (-1.97%)
(As of 02/29/2024 ET)
Today's Range
$45.24
$48.45
50-Day Range
$19.86
$48.84
52-Week Range
$11.85
$51.35
Volume
36,566 shs
Average Volume
184,770 shs
Market Capitalization
$411.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$94.67

Praxis Precision Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
102.4% Upside
$94.67 Price Target
Short Interest
Healthy
4.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of Praxis Precision Medicines in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($19.86) to ($10.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

504th out of 958 stocks

Pharmaceutical Preparations Industry

240th out of 450 stocks


PRAX stock logo

About Praxis Precision Medicines Stock (NASDAQ:PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Stock Price History

PRAX Stock News Headlines

Praxis Precision Medicines Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
PRAX Mar 2024 22.500 put
PRAX Mar 2024 40.000 put
Praxis Precision Medicines Inc (PRAX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/29/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$94.67
High Stock Price Target
$150.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+114.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-214,030,000.00
Pretax Margin
-7,120.70%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$24.22 per share

Miscellaneous

Free Float
8,555,000
Market Cap
$388.34 million
Optionable
Optionable
Beta
2.87
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Marcio Silva De'Souza M.B.A. (Age 45)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Timothy Edwin Kelly (Age 50)
    CFO & Treasurer
    Comp: $633.49k
  • Dr. Steven Petrou B.Sc. (Hons.)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola
    VP of Finance & Principal Accounting Officer
  • Dr. Karl Hansen Ph.D.
    Chief Technical Operations Officer
  • Alex Kane
    VP of Investor Relations & Corporate Communications
  • Mr. Alex Nemiroff J.D. (Age 45)
    General Counsel & Secretary
  • Ms. Kelly McCue
    Chief People Officer
  • Ms. Alyssa J. S. Wyant (Age 49)
    Chief Regulatory & Quality Officer
  • Ms. Megan T. Sniecinski (Age 42)
    Chief Business Officer














PRAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRAX shares.
View PRAX analyst ratings
or view top-rated stocks.

What is Praxis Precision Medicines' stock price target for 2024?

5 Wall Street research analysts have issued 12-month target prices for Praxis Precision Medicines' stock. Their PRAX share price targets range from $29.00 to $150.00. On average, they expect the company's share price to reach $94.67 in the next year. This suggests a possible upside of 102.4% from the stock's current price.
View analysts price targets for PRAX
or view top-rated stocks among Wall Street analysts.

How have PRAX shares performed in 2024?

Praxis Precision Medicines' stock was trading at $22.28 at the beginning of the year. Since then, PRAX shares have increased by 110.0% and is now trading at $46.78.
View the best growth stocks for 2024 here
.

Are investors shorting Praxis Precision Medicines?

Praxis Precision Medicines saw a decline in short interest in February. As of February 15th, there was short interest totaling 348,900 shares, a decline of 38.1% from the January 31st total of 564,000 shares. Based on an average daily volume of 142,200 shares, the days-to-cover ratio is currently 2.5 days. Currently, 4.3% of the company's shares are short sold.
View Praxis Precision Medicines' Short Interest
.

When is Praxis Precision Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our PRAX earnings forecast
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its quarterly earnings data on Wednesday, November, 3rd. The company reported ($15.00) earnings per share for the quarter, missing analysts' consensus estimates of ($13.95) by $1.05.

When did Praxis Precision Medicines' stock split?

Shares of Praxis Precision Medicines reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Verition Fund Management LLC (8.00%), Point72 Asset Management L.P. (7.87%), PFM Health Sciences LP (7.47%), Vanguard Group Inc. (4.22%), Velan Capital Investment Management LP (3.93%) and Sphera Funds Management LTD. (3.74%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Jill Desimone, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends
.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRAX) was last updated on 2/29/2024 by MarketBeat.com Staff